Clear Labs develops fully automated next-generation sequencing platforms and workflows for pathogen detection and genomic analysis. Founded in 2014 and headquartered in San Carlos, California, the company has raised over $120 million to build technology serving clinical diagnostics, food safety, and infectious disease surveillance.
Clear Dx, the company's flagship platform, automates the detection and analysis of infectious disease pathogens in laboratory settings. The platform has achieved penetration across over 50% of U.S. public health laboratories, supporting facilities in states including California, New York, Nebraska, Nevada, and Kansas. During the COVID-19 pandemic, Clear Labs expanded its sequencing technology from food safety applications into SARS-CoV-2 surveillance and wastewater monitoring.
Beyond infectious disease, the company operates in food safety testing with automated, NGS-based solutions for analyzing food before it reaches consumers. More recently, Clear Labs launched oncology-focused NGS workflows to serve research and clinical applications in that domain.
